Vortioxetine Hydrobromide

CHEMBL2107387 Phase 4 Одобрено Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
379.4 g/mol
LogP
Phase
4

A hydrobromide form of vortioxetine with the same therapeutic properties. This multimodal antidepressant is used to treat major depressive disorder and works by both blocking serotonin reuptake and modulating multiple serotonin receptor subtypes, which may offer benefits for mood and cognitive function.

Молекулярная масса

379,4000 g/mol

TPSA

40,60 Ų

Терапевтические области

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Br.Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1

InChI

InChI=1S/C18H22N2S.BrH/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20;/h3-8,13,19H,9-12H2,1-2H3;1H

Molecular Formula

C18H23BrN2S

HBD / HBA

2 / 3

Вращаемые Связи

3

Тяжёлые Атомы

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

A hydrobromide form of vortioxetine with the same therapeutic properties. This multimodal antidepressant is used to treat major depressive disorder and works by both blocking serotonin reuptake and modulating multiple serotonin receptor subtypes, which may offer benefits for mood and cognitive function.

Yes, Vortioxetine Hydrobromide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2107387. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 56843850. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.